Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 10INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Other solid neoplasm 5Gastrointestinal 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Melanoma 111Neoplasms 66Carcinoma, Renal Cell 60Colorectal Neoplasms 43Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 35Carcinoma, Hepatocellular 33Carcinoma, Transitional Cell 27Lung Neoplasms 23Pancreatic Neoplasms 22Triple Negative Breast Neoplasms 21Ovarian Neoplasms 21Head and Neck Neoplasms 21Advanced Cancer 19Breast Neoplasms 17Urinary Bladder Neoplasms 15Small Cell Lung Carcinoma 14Kidney Neoplasms 13Recurrence 11Hodgkin Disease 11Uterine Cervical Neoplasms 10Skin Neoplasms 10Lymphoma 10Solid Tumor 9Mesothelioma 9Endometrial Neoplasms 9Carcinoma, Merkel Cell 9Carcinoma 9

Interventions

Pemetrexed 13Cisplatin 12Nivolumab 5Carboplatin 5pembrolizumab 4Ipilimumab 4Cyclophosphamide 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3fludarabine 3defactinib 3amatuximab 2Paclitaxel 2Gemcitabine 2Drug Therapy 2tremelimumab 1tazemetostat 1osimertinib 1napabucasin 1enzalutamide 1bemcentinib 1abemaciclib 1VS-5584 1Trabectedin 1Thiostrepton 1Safety 1Panobinostat 1Monatide (IMS 3015) 1Midazolam 1Letrozole 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma, Malignant × Nivolumab × Clear all
NCT06097728 2026-04-28

eVOLVE-Meso

AstraZeneca

Phase 3 Recruiting
825 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT05136677 2026-01-23

CheckMate 6DW

Bristol-Myers Squibb

Phase 2 Completed
102 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT04013334 2022-06-16

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Momotaro-Gene Inc.

Phase 2 Unknown
12 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡